Solstice Oncology raised $225 million through a Series A to advance a next-generation CTLA-4 immunotherapy program built from Harbour BioMed technology. The company said it is targeting limitations seen with earlier CTLA-4 approaches by advancing a therapy it believes can shift the immunologic effect profile. The funding round strengthens Solstice’s runway for trial execution as the biotech moves the asset into later development. It also signals continued appetite for checkpoint-targeted platforms beyond conventional CTLA-4 implementations. For investors, the deal highlights a pattern of China-origin innovation being re-packaged into Western-style development and financing structures for global clinical execution.